rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

West Pharmaceutical Services, Inc.

WST · NYSE

Health CareMedical DevicesLeading

WST stood above a rising 150-day average in 40 of the last 52 weekly readings, including each of the last 27 weeks. It is 17.7% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
27 in a row
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$13.1M
Officials’ trades on record
29

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 40 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$10.5M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

29 disclosed lines: House 24, Senate 3, executive 2; 12 people.

WhoDidAmountTraded
Arjun Mody Executive branch: Office of Government EthicsSocial Security Administrationsold$1k–$15k30 Jan 2026filed 10 Apr 2026
Lisa C. McClain House: U.S. House ClerkMI09soldspouse$1k–$15k22 Jul 2025filed 13 Aug 2025
Lisa C. McClain House: U.S. House ClerkMI09boughtspouse$1k–$15k17 Jun 2025filed 13 Aug 2025
Stephen I. Miran Executive branch: Office of Government EthicsCouncil of Economic Adviserssold$15k–$50k9 Jun 2025filed 6 Sep 2025
Robert P. Bresnahan, Jr. House: U.S. House ClerkPA08sold$1k–$15k8 Apr 2025filed 8 May 2025
Robert P. Bresnahan, Jr. House: U.S. House ClerkPA08bought$1k–$15k25 Feb 2025filed 27 Mar 2025
Jared Moskowitz House: U.S. House ClerkFL23solddependent child$1k–$15k13 Feb 2025filed 6 Mar 2025
Jared Moskowitz House: U.S. House ClerkFL23sold$1k–$15k8 Nov 2024filed 9 Dec 2024
Jared Moskowitz House: U.S. House ClerkFL23bought$1k–$15k28 Dec 2023filed 21 Aug 2024
Jared Moskowitz House: U.S. House ClerkFL23boughtdependent child$1k–$15k28 Dec 2023filed 22 Jan 2024
Jared Moskowitz House: U.S. House ClerkFL23bought$1k–$15k14 Jul 2023filed 21 Aug 2024
Tommy Tuberville Senate: U.S. Senate eFDSenatorsoldjoint$1k–$15k30 Mar 2022filed 8 Apr 2022

Insiders

Buy orders, 12 months0
Sale orders, 12 months6
Buyers · sellers0 · 2
WhoDidSharesTraded
Annette F. FavoriteSr. VP & Chief HR Officersold2,524at $365.0015 Sep 2026filed 15 Sep 2026
Annette F. FavoriteSr. VP & Chief HR Officersold2,500at $355.0014 Sep 2026filed 15 Sep 2026
Annette F. FavoriteSr. VP & Chief HR Officersold2,500at $345.0011 Sep 2026filed 15 Sep 2026
Annette F. FavoriteSr. VP & Chief HR Officersold2,817at $340.818 Sep 2026filed 10 Sep 2026
Annette F. FavoriteSr. VP & Chief HR Officersold2,818at $340.818 Sep 2026filed 10 Sep 2026
Annette F. FavoriteSr. VP & Chief HR Officersold2,500at $340.818 Sep 2026filed 10 Sep 2026
Chad WintersVP, Chief Accounting Officersold896at $300.6727 Apr 2026filed 29 Apr 2026
Annette F. FavoriteSr. VP & Chief HR Officersold2,817at $305.2027 Apr 2026filed 29 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

Everyone who traded it

Janet Brutschea Haugen Company insiderDirector · last 30 Sep 20260 · 0
Annette F. Favorite Company insiderSr. VP & Chief HR Officer · last 15 Sep 20260 · 8
Michel Lagarde Company insiderPresident and CEO · last 8 Sep 20260 · 0
Robert W. McMahon Company insiderSVP & Chief Financial Officer · last 11 Aug 20260 · 0
Shane Alden Campbell Company insiderSVP, Proprietary Segment · last 12 May 20260 · 0
Deborah L. Keller Company insiderDirector · last 4 May 20260 · 0
Douglas A. Michels Company insiderDirector · last 4 May 20260 · 0
Goldman Myla Lai Company insiderDirector · last 4 May 20260 · 0
Mark A. Buthman Company insiderDirector · last 4 May 20260 · 0
Molly Joseph Company insiderDirector · last 4 May 20260 · 0
Paolo Pucci Company insiderDirector · last 4 May 20260 · 0
Robert F. Friel Company insiderDirector · last 4 May 20260 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202535.9%
Operating profit marginFY 2025 · to 31 Dec 202519.0%
Free cash flow marginFY 2025 · to 31 Dec 202515.3%
Return on capital employedFY 2025 · to 31 Dec 202516.2%
Cash conversionFY 2025 · to 31 Dec 2025153%
Debt to equityFY 2025 · to 31 Dec 20250.06×
Interest coverFY 2025 · to 31 Dec 202538.74×
Research spendFY 2025 · to 31 Dec 20252.4%
Share count trendFY 2025 · to 29 Jan 20260.0%
Cash and equivalentsFY 2025 · to 31 Dec 2025$791.3M
Free cash flowFY 2025 · to 31 Dec 2025$468.9M

Analyst forecasts

No analyst forecasts yet.